Tag: Insulin
DDW: Endoscopic Procedure May Eliminate Insulin Use in T2DM
Recellularization via electroporation therapy followed by GLP1-RA treatment resulted in elimination of insulin therapy for most patients
Sanofi Follows Lilly, Novo Nordisk in Cutting Insulin Prices
Sanofi is the third company to cut prices on its insulin products and cap out-of-pocket charges to $35 a month
Closed-Loop Glucose System Beneficial for Young Children With Type 1 Diabetes
Greater percentage of time with glucose level in target range seen for young children using closed-loop system
Novo Nordisk to Cut Insulin Prices by Up to 75 Percent
News follows similar move made by Eli Lilly, which said earlier this month that it will cut insulin prices by 70 percent
Eli Lilly to Slash Insulin Prices, Cap Monthly Out-of-Pocket Costs at $35
Company will cut its list price for Humalog 100 units/mL starting in the fourth quarter of 2023
2009 to 2018 Saw Increase in Total Expenditure for Insulin
Out-of-pocket cost of insulin increased from $1,678 to $2,800 per person per year in pre- to post-ACA period for uninsured population
Fully Closed-Loop Insulin Delivery System Improves Glucose Control in T2DM
Improved glucose control seen with no increase in hypoglycemia compared with standard insulin therapy
Guidelines Updated for Reducing Hypoglycemia Risk in Diabetes
Strong recommendations include use of glucagon preparations that do not need reconstitution, real-time CGM for those receiving multiple daily injections
Racial, Socioeconomic Disparities in Insulin Pump Use Persist
Lower odds ratios seen for insulin pump use for Hispanic, Black, other race versus White; with lower education, lower household income
Insulin Rationing Reported by 16.5 Percent of Insulin Users
Variation seen among subgroups, with rationing in 11.2 percent of those aged 65 years and older and 20.4 percent of younger persons
